CR11836A - Prueba de diagnostico inmediato para la deteccion de exposicion o inmunidad contra el virus del dengue - Google Patents

Prueba de diagnostico inmediato para la deteccion de exposicion o inmunidad contra el virus del dengue

Info

Publication number
CR11836A
CR11836A CR11836A CR11836A CR11836A CR 11836 A CR11836 A CR 11836A CR 11836 A CR11836 A CR 11836A CR 11836 A CR11836 A CR 11836A CR 11836 A CR11836 A CR 11836A
Authority
CR
Costa Rica
Prior art keywords
dengue virus
diagnostic test
exposure
immunity against
detection
Prior art date
Application number
CR11836A
Other languages
English (en)
Inventor
Kumar Sil Bijon
yun ying Tan
Original Assignee
Mp Biomedicals Asia Pacific Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mp Biomedicals Asia Pacific Pte Ltd filed Critical Mp Biomedicals Asia Pacific Pte Ltd
Publication of CR11836A publication Critical patent/CR11836A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención provee una "prueba de diagnóstico inmediato" (PDCT) para detectar a un sujeto que ha estado expuesto al virus del dengue o parte inmunológica del mismo o quien ha logrado algún nivel de inmunidad contra un antígeno del virus del dengue.
CR11836A 2008-05-15 2010-12-09 Prueba de diagnostico inmediato para la deteccion de exposicion o inmunidad contra el virus del dengue CR11836A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG200803904-2A SG157244A1 (en) 2008-05-15 2008-05-15 Point of care test for the detection of exposure or immunity to dengue virus

Publications (1)

Publication Number Publication Date
CR11836A true CR11836A (es) 2011-06-07

Family

ID=41318932

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11836A CR11836A (es) 2008-05-15 2010-12-09 Prueba de diagnostico inmediato para la deteccion de exposicion o inmunidad contra el virus del dengue

Country Status (7)

Country Link
BR (1) BRPI0915291A2 (es)
CO (1) CO6311040A2 (es)
CR (1) CR11836A (es)
EC (1) ECSP10010680A (es)
MX (1) MX2010012363A (es)
SG (1) SG157244A1 (es)
WO (1) WO2009139725A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG165194A1 (en) * 2009-03-20 2010-10-28 Mp Biomedicals Asia Pacific Pte Ltd Point of care test for the detection of exposure to hev immunoglobulin a (iga)
CN102393454A (zh) * 2011-08-24 2012-03-28 中国检验检疫科学研究院 检测登革病毒抗体的胶体金试纸条及其制备方法和应用
CA3177572C (en) 2013-03-15 2026-02-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for dengue virus chimeric constructs in vaccines
SG10201404571PA (en) * 2014-08-01 2016-03-30 Mp Biomedicals Asia Pacific Pte Ltd Method and kit for detecting a dengue virus infection
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
CN112912106A (zh) 2018-09-05 2021-06-04 武田疫苗股份有限公司 登革热疫苗单位剂量及其施用
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
WO2021202992A2 (en) * 2020-04-03 2021-10-07 Lawrence Loomis Rapid point of care assay for the detection of the asymptomatic carrier state of covid-19
US20230204574A1 (en) * 2020-04-24 2023-06-29 Massachusetts Institute Of Technology Rapid, point of care detection of neutralizing antibodies against a virus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03148066A (ja) * 1989-11-06 1991-06-24 Nippon Zeon Co Ltd ウイルス感染症診断用メンブレンおよび診断方法
KR20010022452A (ko) * 1997-07-31 2001-03-15 추후제출 플라비바이러스 감염에 대한 재조합 다이머형 엔벨롭 백신
FR2767324B1 (fr) * 1997-08-14 2001-04-06 Pasteur Institut Utilisation de proteines d'enveloppe recombinantes pour le diagnostic du virus de la dengue
WO2005014627A1 (en) * 2003-08-07 2005-02-17 International Centre For Genetic Engineering And Biotechnology Recombinant dengue multi epitope proteins as diagnostic intermediates
SG137711A1 (en) * 2006-05-11 2007-12-28 Nat Environment Agency Antigen capture anti-dengue iga elisa (aca-elisa) for the detection of a flavivirus specific antibody

Also Published As

Publication number Publication date
CO6311040A2 (es) 2011-08-22
BRPI0915291A2 (pt) 2016-02-16
ECSP10010680A (es) 2011-04-29
WO2009139725A1 (en) 2009-11-19
SG157244A1 (en) 2009-12-29
MX2010012363A (es) 2011-04-11

Similar Documents

Publication Publication Date Title
BR112013033418A2 (pt) método e aparelho para testar infratores no uso de drogas
BR112015022763A8 (pt) sensor para detectar um analito
BR112012030552A2 (pt) composição imunogênica
MX340916B (es) Metodos para detectar señales de identificacion de enfermedad o condiciones en fluidos corporales.
BR112014013082A2 (pt) método para detectar adutos nucleossomos
MX2009008140A (es) Vacunas a base de antigeno dirigido a dcir expresado en celulas que presentan antigeno.
EP2078083A4 (en) NEW DOG INFLUENZA VIRUS AND VEGETABLE THEREFOR
MX2015012437A (es) Esteroides neuroactivos, composiciones, y usos de los mismos.
ATE493290T1 (de) Alcotestgerät
CO6160335A2 (es) Vacuna
ES2422735T3 (es) Procedimiento para la predicción de un riesgo de reacciones adversas a medicamentos mediante la determinación de HLA-B 1502
MX340547B (es) Equipos de prueba de diagnostico.
BR112013023540A2 (pt) anticorpo, kit e método para a determinação de peptídeos amilóides
CO6690763A2 (es) Anticuerpo específico de miostatina y composiciones que lo contienen
BR112015023421A2 (pt) método e sistema de inspeção de lâminas de turbinas eólicas com a base no solo
CO6551750A2 (es) Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio
MX2014003988A (es) Sistema de monitoreo para monitorear un paciente y detectar delirio del paciente.
BR112013020743A2 (pt) composições e métodos para a terapia e diagnóstico de influenza
BR112017002209A2 (pt) método e kit para detectar uma infecção pelo vírus da dengue
BR112015001414A2 (pt) composição antideriva
UY30837A1 (es) Uso de genes de suero amiloide a en el diagnostico y tratamiento del glaucoma e identificacion de agentes antiglaucoma
CO6311040A2 (es) Punto de prueba de cuidado para deteccion de un sujeto expuesto al virus del dengue o que ha alcanzado cierto nivel de inmunidad contra un antigeno del virus del dengue
CY1116083T1 (el) Μεθοδος για τον εντοπισμο τυπων του ιου των ανθρωπινων θηλωματων (hpv)
BR112012007888A2 (pt) "métodos de tratamento usando anticorpos anti-ldl oxidada".
UY38393A (es) Anticuerpos contra bcma soluble

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)